Find Clinical Trials

Inclusion Criteria: 1. Age ≥ 18 years old. 2. Premenopausal and postmenopausal stage II-III females or males (patients with multicenter and/or multifocal early-invasive breast cancer) if all histopathological examination of tumors meet the pathological criteria of ER and/or PR\>10% and HER2- (HER2 expression 0 or 1+ or 2+ and negative FISH test). 3. Patients must have histologically confirmed ER and/or PR \>10%, HER2-, early invasive breast cancer. 4. Intolerance or insensitivity to neoadjuvant chemotherapy: 2 cycles of neoadjuvant chemotherapy, tumor evaluation PD/SD, advanced age, and inability to tolerate chemotherapy with underlying diseases. 5. ECOG PS score 0-2. 6. Patients must be able and willing to swallow and retain oral medications. 7. Premenopausal women within 14 days of enrollment, or women with amenorrhea for less than 12 months at the time of enrollment, must have a negative serum or urine pregnancy test. 8. Patients who have received neoadjuvant endocrine therapy are eligible for enrollment as long as they are enrolled within 6 months of initial histologic diagnosis and have completed no more than 2 months of neoadjuvant endocrine therapy. 9. Absolute neutrophil count ≥ 1500/µL, platelet ≥ 100000/mm3, hemoglobin ≥ 10g/dL Exclusion Criteria: 1. Prior treatment with any CDK inhibitor. 2. Inflammatory breast cancer or stage IV breast cancer or bilateral breast cancer. 3. History of anaphylaxis caused by chemical or biologic components similar to dalsily. 4. Patients who have received any drugs or substances with effective CYP3A isoenzyme inhibitors or inducers within 7 days of enrollment. 5. Uncontrolled intercurrent illness that would limit compliance with study requirements. 6. Pregnant women or women of childbearing potential with a negative pregnancy test within 14 days prior to admission. 7. Patients with any history of malignancy are not eligible. 8. Patients who have received endocrine therapy within 5 years prior to the diagnosis of the current malignancy.

Inclusion Criteria: * Sign the informed consent form before the trial to fully understand the purpose, process and possible adverse reactions of the trial; * Age 18 \~ 75 years old, gender is not limited; * Documented physician diagnosis of asthma at least 12 months prior to Visit 1; * Subjects who received high-dose Inhaled Corticosteroids (ICS) in asthma control medications prescribed by their physicians at least 6 months prior to Visit 1; * There must be a record of receiving a stable total daily dose of ICS at least 3 months prior to visit 1; * There must be a record of the use of other asthma control medications at a stable dose at least 3 months prior to visit 1; For subjects taking maintenance oral hormones, the dose of oral hormones is up to 10mg prednisone per day or 20mg every other day (or equivalent) and must be stable for at least 30 days prior to visit 1 and during treatment. * Documented at least 2 asthma exacerbations in the 12 months prior to Visit 1 and no major asthma exacerbation events in the 1 month prior to signing informed. Exclusion Criteria: * Have a clinically significant lung disease other than asthma； * Pre-existing autoimmune disease; * A history of known or suspected immunosuppression, including a history of invasive opportunistic infections; * Any disease that has not been determined to be stable by the investigator； * Cancer history: Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ are eligible to be enrolled in this study if they had completed curative therapy for at least 12 months prior to visit 1. Patients with other malignancies who had completed curative treatment for at least 5 years prior to visit 1 could be enrolled in the study. * Current smoker or smoking history ≥10 pack-years (former smokers with smoking history \<10 pack-years had quit smoking less than 6 months before interview 1); * Other factors determined by the investigator that subjects were not suitable to participate in the study.

Inclusion Criteria: * Adolescents age 12-18 * Current moderate to severe depression (PHQ-9-M \> 11) * Current clinically significant anhedonia, operationalized as PHQ-9-M anhedonia item score \> 1 * English language fluency and literacy level sufficient to engage in study protocol * Willing to download the app on their smart phones Exclusion Criteria: * Evidence of mania, psychosis, or developmental disability precluding comprehension of study procedures per electronic health record review and phone screen.

Inclusion Criteria: * Familial inherited breast cancer with genetic variants, including but not limited to mutations in the BRCA1, BRCA2, TP53, and PALB2 genes * The patient had no major organ dysfunction * ECOG score 0-1 Exclusion Criteria: * There are serious dysfunction of vital organs (heart, liver, kidney) * Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years * In other acute infectious disease or chronic infectious disease activity period * A history of uncontrolled seizures, central nervous system disorders, or mental disorders

Inclusion Criteria: 1. Patients with newly diagnosed breast cancer by pathology 2. Age 18-60 years 3. ECOG 0-2 4. CIPN patients with NCI-CTCAE grade 1 or higher after treatment with paclitaxel-based drugs Exclusion Criteria: 1. Patients with contraindications to hyperbaric oxygen i. Untreated pneumothorax. ii. concomitant administration of disulfiram. iii. concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. iv. premature and/or low body mass newborns. iv. Premature and/or low body mass neonates. 2. Other cancers

Inclusion Criteria: * Male or female, aged \>= 18 and \< 65. * Ability to access applications on mobile device, technical understanding and minimal technological skills * Subject has provided informed consent and is willing to comply with the study procedures. Exclusion Criteria: * Subject does not consent to the study * Subject does not comply with inclusion criteria * Subject has a known allergy to medical adhesives

Inclusion Criteria: * Married women aged 15-24 years, their husbands and MILs sharing a household; * Living in the catchment area with no stated intention of leaving during the study period; * Participants speaking in Maithili or Nepali; * Wife reporting Intimate Partner Violence (physical, sexual or abusive control) in last 12 months as measured by three questions from the International Violence Against Women Survey (IVAWS); * Expressing desire to remain in the current relationship/family Exclusion Criteria: * Pregnant women; * History of IPV severe enough to result in hospitalization in the past 12 months; * Significant cognitive problems/disability precluding participation; * Any participant with Severe Alcohol Dependence, defined as Severity of Alcohol Dependence Questionnaire (SADQ) \> 31 (those with mild to moderate dependance will be referred but not excluded)

Inclusion Criteria: * \>18 yrs old breast cancer ( pathological proved ) * Stage II/III breast cancer * High risk local recurrence ( LVI/ G3/ LN positive) * Non metastatic breast cancer Exclusion Criteria: * Thyriod dysfunction of any othe cause( no known pretreatment primary thyroid disease or dysfunction; no prior thyroid surgery; and no prior RT that involved the hypothalamic-pituitary axis or thyroid

Inclusion Criteria: * The patient has a biopsy-confirmed diagnosis of stage II-III TNBC 1. Patients with tumor stage T1cN1-2, T2N0-N2, T3N0-N2, T4N0-N2 2. ER and PR negative is defined as an absent or minimal (≤10%) expression of oestrogen and progesterone receptors and absence of HER2 protein over-expression per ASCO/CAP-guidelines 3. All histological subtypes are eligible, including but not limited to invasive breast cancer of no special type (NST) , invasive lobular carcinoma (ILC) etc * WHO/ECOG performance status of grade 0-1 * The participant is able to perform a CPET test (cardiopulmonary exercise testing) * Body mass index ≥ 18.5 kg/m² * Pregnant or breastfeeding women * Presence of adequate bone marrow and organ function * HbA1c \<10% Exclusion Criteria: * had a treatment with any of the following: 1. any other chemotherapy, immunotherapy or anticancer agents within 5 years of the first dose of study treatment 2. injectable hypoglycemics 2. have not have recovered adequately from the toxicity and/or complications from a surgical intervention prior to starting therapy * prior systemic treatment for breast cancer or other malignancies within 5 years of treatment enrollment, except for adequately treated basal cell or squamous skin cancer or in situ cervical cancer. Other malignancies diagnosed more than 5 years before the diagnosis of breast cancer must have been radically treated without evidence of relapse at the moment of patient enrollment in the trial. * has a history of an additional malignancy that is progressing or that has required active treatment in the 5 years prior to breast cancer diagnosis. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer * Prior treatment with anthracyclines * Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) * Has any disorder, which in the Investigator's opinion might jeopardize the participant's safety or compliance with the protocol * Has, as judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Screening for chronic conditions is not required * Active autoimmune diseases requiring systemic treatments * Patients with type 1 diabetes mellitus * History of alcohol use disorder (DSM-5) * History of eating disorder (DSM-5)

Inclusion Criteria: * 18 years or older * Clinical diagnosis of T2D ≥ one year * Using at least one AHA * Status as a Sun Life group benefits member, initiates isCGM device through Lumino Health™ Pharmacy, and completes one initial pharmacist consultation (isCGM cohort) or completes 2 or more diabetes coaching program consultations (isCGM+coaching cohort); or has private health insurance and uses CBG monitoring (CBG cohort) * Baseline HbA1c ≥ 7.0% * ≥ 1 HbA1c value up to 6 months prior to index date * Exclusive use of isCGM for ≥ 3 months * Informed consent Exclusion Criteria: * Have a history of insulin use * Are pregnant or breastfeeding at the time of study enrollment or become pregnant during the study * Have an estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 * Previously used rtCGM or isCGM for \> 3 months * Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date

Inclusion Criteria: * Meets the diagnostic criteria for type 2 diabetes in the "China Type 2 Diabetes Prevention and Treatment Guidelines (2020 Edition)"; * Aged between 20 and 79 years old, without other severe underlying diseases; ③ Possesses full cognitive and literacy abilities; ④ Volunteers to participate in this study and are willing to sign an informed consent form. Exclusion Criteria: * Those who have been diagnosed with type 1 or other types of diabetes; * Those with severe cardiac, pulmonary, hepatic, or renal insufficiency; * Those with mental confusion, speech disorders, or dementia, etc.; * Those who are unable to take care of themselves, bedridden, or have mobility impairments; ⑤ Women who are breastfeeding or pregnant; * Those with a recent history of surgery, trauma, acute major vascular complications, or infectious diseases.

Inclusion Criteria: 1. Physician-confirmed clinical diagnosis of asthma according to GINA guidelines 2. Uncontrolled asthma according to the physician's clinical assessment despite the use of appropriate therapy of Step 2 or 3, according to GINA guidelines 3. Patients who are eligible for the use of Foster Nexthaler 100/6 mcg according to the SmPC 4. Inhaled asthma therapy was changed independent from the study to Foster Nexthaler 100/6 mcg DPI maximum 1 week prior to OR on the day of study inclusion 5. Spirometry was performed as part of routine clinical practice 6. Patient able to use their Foster Nexthaler device properly after education on inhaler technique 7. Patient provided written, informed consent to study participation 8. Patient ≥ 18 years of age Exclusion Criteria: 1. Participation in any clinical trial, 30 days prior to inclusion 2. Patient is unable to execute a spirometry test 3. Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment. 4. Patients with other significant diseases of the respiratory system or other organ systems that may significantly contribute to asthma symptoms (such as severe heart failure, symptomatic anaemia, functional respiratory disorders, malignant diseases etc.) according to the physician's clinical assessment. 5. Continuous use of oral corticosteroids (\>5 mg prednisolone/day or \>4 mg methylprednisolone/day) 6. Use of continuous oxygen therapy 7. Use of biologics for asthma treatment 8. All exclusion criteria listed in Foster Nexthaler 100/6 SmPC

Inclusion Criteria: * At least 18 years old * ECOG ≤ 2 * Stage 0-III HR+ breast cancer in need of strategies to reduce symptoms and improve quality of life Exclusion Criteria: • Less than 18 years of age. \- Stage 4 HR+ breast cancer

Inclusion Criteria: Part 1 * Voluntary consent to participate in this study must be given (in writing) * Japanese healthy adults or non-Asian healthy men 18 to \< 55 years at the time of informed consent ( Japanese healthy adults 65 to \< 80 years for the elderly cohort) * BMI is within the specified range at screening Inclusion Criteria: Part 2 * Voluntary consent to participate in this study must be given (in writing) * Japanese patients with essential hypertension, aged 18 to \<65 years at the time of informed consent * BMI is within the specified range at screening Inclusion Criteria: Part 3 * Voluntary consent to participate in this study must be given (in writing) * Japanese patients with essential hypertension, aged 18 to \<80 years at the time of informed consent * BMI is within the specified range at screening Exclusion Criteria: Part 1 * History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator. * History of or current drug allergy * History of or current alcoholism or drug addiction * Smoking within the specified period * infection within the specified period * Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study Exclusion Criteria: Part 2 * History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator. * History or of current drug allergy * History of or current alcoholism or drug addiction * Pregnant or breastfeeding patients, or patients willing to have a child during the study * Smoking within the specified period * infection within the specified period * Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study Exclusion Criteria: Part 3 * History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator. * History or of current drug allergy * History of or current alcoholism or drug addiction * Pregnant or breastfeeding patients, or patients willing to have a child during the study * Smoking within the specified period * infection within the specified period * Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study

Inclusion Criteria: * Self-identified first-generation SAI woman aged 40-65 years without breast cancer diagnosis (permanent residency in US or are in the process of obtaining permanent residency) * Insufficiently active (self-reported \<150 minutes/week of moderate-intensity or \<75 minutes/week of vigorous-intensity PA in the past month) * Conversant in Hindi * Owns a smartphone for Fitbit application * Has a computer or mobile device with Internet access * Willing to participate in recorded Virtual intervention sessions * Medical clearance if has Type 1 diabetes, or Type 2 diabetes with an A1C ≥ 9.0%, or have an A1C of ≥ 6.5% without a prior diabetes diagnosis * Has no disabilities preventing regular PA determined by Physical Activity Readiness Questionnaire (PAR-Q \& You) Exclusion Criteria: * Major signs/symptoms of pulmonary or CVD, unstable cardiac or pulmonary disease in the past month, or other conditions interfering with walking (per PAR-Q \& You) * Systolic BP ≥160 and/or diastolic BP ≥100

Inclusion criteria: 1. Age between 12\~75 years old (including the critical value), male and female, weight ≥ 30kg; 2. Diagnosed with asthma for at least 1 year and current disease status that meets the diagnostic criteria of the 2024 GINA guidelines, and: 1\) Subjects have received moderate-high dose ICS therapy for at least 2 consecutive months before screening (see Appendix 5 for details, fluticasone propionate ≥250 μg twice a day, or an equivalent dose of ICS, no more than 2000 μg/day or equivalent dose of fluticasone propionate) combined with 1 control drug (such as LABA, LTRA, LAMA or extended-release theophylline), and maintained a stable treatment regimen and dose therapy for ≥ 1 month before baseline. Subjects using the third control drug can also participate in the study, but the subjects must also use the third control drug for at least 2 consecutive months before screening, and maintain a stable treatment regimen and dose treatment ≥ 1 month before baseline; 2) 1-second forced expiratory volume (FEV1) before bronchodilator use at the screening and baseline visits, measured ≤ 80% of the normal predicted value for adults and 90% of the normal predicted value ≤ for adolescents; 3) Asthma Control Questionnaire-5 (ACQ-5) score ≥ 1.5 points at the screening and baseline visits; 4) Must have experienced ≥ 1 acute exacerbation event within 12 months prior to screening: need to receive 1 ≥ systemic glucocorticoids (oral or intravenous) treatment due to asthma exacerbation or need hospitalization/emergency treatment; 5）A positive bronchodilator test (a ≥12% increase in FEV1 after inhalation of bronchodilators and an absolute increase in FEV1 ≥200 mL) will be acceptable for bronchodilator test results within 24 months prior to screening； Positive bronchodilator test (after inhaling a bronchodilator, the forced expiratory volume in one second (FEV1) increases by ≥12%, and the absolute value of FEV1 increases by ≥200 mL). The results of the bronchodilator test conducted within 24 months before screening are acceptable. 3.The subjects (including adolescents aged 12 years old ≤ age \< 18 years old) agree that they themselves and their partners will adopt effective contraceptive measures from the signing of the Informed Consent Form (ICF) until 6 months after the last administration of the drug. 4.The subject and his/her guardian (applicable to adolescents aged 12 years old ≤ age \< 18 years old) are able to understand the procedures and methods of this study, willing to sign the Informed Consent Form, strictly abide by the clinical research protocol to complete the study, and capable of independently completing the study-related questionnaires. Exclusion criteria: 1. Subjects with known hypersensitivity to the investigational product or its excipients; 2. Subjects who, within 1 month prior to screening and drug administration, have required systemic glucocorticoid therapy (oral or intravenous) for asthma exacerbation at least once, or have required hospitalization/emergency treatment due to asthma exacerbation. 3. Subjects who, within 1 month prior to screening and drug administration, have required at least one course of systemic glucocorticoid therapy (oral or intravenous administration) for asthma exacerbation, or have required hospitalization or emergency treatment due to asthma exacerbation. 4. Subjects who have received systemic glucocorticoid therapy from 1 month before screening until drug administration (excluding those with topical, ophthalmic, or intranasal glucocorticoid use) 5. Subjects who have received intravenous immunoglobulin (IVIG) therapy or allergen-specific immunotherapy (SIT) within 1 month prior to drug administration. 6. Subjects who have undergone major surgery within 8 weeks prior to screening have scheduled major surgery during the study period, including inpatient and day-case outpatient procedures. 7. Subjects with a history of substance abuse or illicit drug use. 8. Subjects with any other conditions that, in the investigator's judgment, may compromise subject safety or trial integrity.

Inclusion Criteria: * Men and postmenopausal women within the Las Vegas/Henderson NV area * Ages 45-80 years * BMI between 25-40 kg/m2 * HbA1c between 5.7-6.4% * Individuals from different demographic backgrounds (i.e., American Indian or Alaska Native, Caucasians, Asian, Black or African-American, Native Hawaiian, Hispanic, Latino or Pacific Islander) * Individuals who are considered "non-frequent" white potato consumers (\<2 servings of baked potatoes/week) * Individuals from all races, genders, sexual identities, and religions will be included * Individuals must follow certain guidelines, including avoiding new medications during the study or significant changes to lifestyle factors (e.g. beginning to smoke or exercise more or less than usual) Exclusion Criteria: * Individuals with uncontrolled hypertension (≥160/100mmHg), active cancer, asthma, thyroid, kidney, liver, or pancreatic diseases * Individuals who are currently using insulin, on dialysis, changing/adding hypoglycemic, anti-hypertensive, and hypocholesterolemic medication within ≤3 months (or throughout the study) * Individuals participating in weight loss programs or another clinical trial * Individuals who start smoking * Individuals who have unstable metabolic or chronic diseases * Individuals who may have allergies to potatoes * Woman who are currently pregnant, think they may be pregnant, or who is nursing cannot participate (women must be postmenopausal)

Inclusion Criteria: * Knowing Turkish * Being literate * Being over 18 * Being primiparous * Having a singleton fetus and cephalic presentation * Being diagnosed with preeclampsia * Agreeing to participate in the study Exclusion Criteria: * Having any additional disease other than preeclampsia * Participant's voluntary withdrawal from the study * Having a cesarean section for any reason

Inclusion Criteria: * 1\) Have completed primary treatment for breast or ovarian cancer (i.e., surgery, chemotherapy, and radiotherapy). * 2\) Be known to carry a BRCA1/2 pathogenic mutation. * 3\) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subscale. * 4\) Be at least 18 years of age. * 5\) Be able to read, understand and express herself in French. Exclusion Criteria: * 1\) Have distant metastases (in the case of ovarian cancer, only stages IV and IIIC will be excluded). * 2\) Be known to carry a BRCA1/2 "VUS" mutation. * 3\) Have a known cognitive disorder. * 4\) Have a known severe psychological disorder (e.g., psychotic disorder, bipolar disorder, substance abuse or dependence disorder). * 5\) Have already taken part in the original FCR group psychotherapy at the CHU de Québec. * 6\) Women taking psychotropic medication are eligible, but only if the dosage has been stable for at least one month.

Inclusion Criteria: * Participants are 18 years or older. * Participants have a diagnosis of ICD-10 F32, F33, F34, F41.1, F41.2, F43 or F43.2. * Participants have minimal relational skills to participate in group therapy. * Participants agree to be part of the study by giving signed written consent. Exclusion Criteria: * Participants have a diagnosis of ICD-10 F10-19, F20-29, F31, F42, F43.1, F60. * Participants with cognitive deficits assessed during the initial interview or diagnosis of ICD-10 F70-79. * Participants with planning or structured suicidal ideation. * Participants with difficulties in relational skills evaluated during the initial interview.